Subgroup analysis of the
primary composite functional endpoint1
CAMZYOS®, n (%)(n=123) | Placebo, n (%) (n=128) | Difference(95% CI); P value |
|
---|---|---|---|
Primary composite functional endpoint measured the change from baseline to week 30 | |||
Either ≥1.5 mL/kg/min increase in pVO2 with ≥1 NYHA class improvement or ≥ 3.0 mL/kg/min increase in pVO2 with no worsening of NYHA class |
45 (37) | 22 (17) | 19% (9, 30); P=0.0005 |
≥1.5 mL/kg/min increase in pVO2 with ≥1 NYHA class improvement |
41 (33) | 18 (14) | 19% (9, 30) |
≥3.0 mL/kg/min increase in pVO2 with no worsening in NYHA class |
29 (23) | 14 (11) | 13% (3, 22) |
- CI=confidence interval; NYHA=New York Heart
Association; pVO2=peak oxygen consumption.
Reference:
- CAMZYOS [package insert]. Princeton, NJ: Bristol-Myers Squibb Company; 2022.